HPV vaccination before pregnancy was linked to lower odds of preterm birth in a Swedish study of 624,713 births.
News|Articles|August 25, 2026
Report: Postpartum depression market expected to grow based on awareness, pipeline progress
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
With brexanolone withdrawn in 2025, zuranolone leads PPD treatment as luvesilocin and LPCN 1154 advance in trials.
Advertisement
Advertisement
The postpartum depression (PPD) treatment market is expected to grow through 2036 across the 7 major markets—the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan—according to a market analysis published by DelveInsight Business Research, LLP. In 2025, the total diagnosed prevalent cases of maternal PPD across these markets were approximately 1.3 million, a figure projected to rise over the forecast period.1
Related to this article
Missed the rollout of ACOG's 2026 Maternal Immunization Schedule? This FAQ breaks down everything clinicians need to know about the new guidance.
The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.
A real-world study presented at Psych Congress found that zuranolone's PPD symptom improvements were sustained through day 90.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
A new 3-part Lancet series reframes pregnancy as a cardiovascular risk window.
Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.
A review finds post-miscarriage ultrasound heterogeneity is common and that symptoms, not endometrial thickness, should guide management after EPL.
Advertisement
Advertisement